Cargando…
Pneumococcal serotype evolution in Western Europe
BACKGROUND: Pneumococcal diseases remain a leading cause of vaccine-preventable death worldwide in children <5 years of age. The seven-valent pneumococcal conjugate vaccine (PCV7) was approved in 2001 in Europe and was introduced into the national immunization programmes of many European countrie...
Autores principales: | Tin Tin Htar, Myint, Christopoulou, Dina, Schmitt, Heinz-Josef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606906/ https://www.ncbi.nlm.nih.gov/pubmed/26468008 http://dx.doi.org/10.1186/s12879-015-1147-x |
Ejemplares similares
-
P246: Evolution of S. pneumoniae serotypes in invasive pneumococcal diseases (IPD) in Western Europe: a literature review
por: Christopoulou, D, et al.
Publicado: (2013) -
A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013) -
Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017
por: Nuttens, Charles, et al.
Publicado: (2022) -
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
por: Hausdorff, William P, et al.
Publicado: (2010) -
Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies
por: Tin Tin Htar, Myint, et al.
Publicado: (2017)